Slide Show: Colorectal Cancer Highlights From ASCO 2014

June 20, 2014

Conference | ASCO Annual Meeting: Colorectal Cancer

This slide show highlights some of the top studies and news on colorectal cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

References:

1. Hong YS, Nam BH, Kim KP, et al. Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 3502. Read More.

2. Venook AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract LBA3. Read More.

3. Koopman M, Simkens L, May AM, et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 3504. Read More.

4. Rodel C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 3500. Read More.

5. Schmoll HJ, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 3531. Read More.

6. Shaik M, Tokala H, Modali R, et al. Effect of exercise and dietary fish consumption on risk of recurrence in colon cancer: A multinational study. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 1514.

Tae Won Kim, MD, discusses results of the ADORE study, which found that treatment with oxaliplatin-containing FOLFOX significantly improved the 3-year disease-free survival of select patients with curatively resected rectal cancer compared with treatment with 5-fluorouracil (FU)/leucovorin. Photo by Â© ASCO/Brian Powers 2014.[1]

Alan P. Venook, MD, presents long-awaited results of the phase III CALGB/SWOG 80405 trial, which found that first-line treatment with a chemotherapy backbone plus either the anti-VEGF bevacizumab (Avastin) or the anti-EGFR cetuximab (Erbitux) resulted in equally effective outcomes for patients with metastatic colorectal cancer and wild-type KRAS. Photo by Â© ASCO/Silas Crews 2014.[2]

Final results of the CAIRO3 study found that maintenance treatment with capecitabine and bevacizumab after 6 cycles of capecitabine/oxaliplatin/bevacizumab (CAPOX B) is an effective treatment in patients with metastatic colorectal cancer. Photo by Â© ASCO/Rodney White 2014.[3]

Results of two trials examining the use of oxaliplatin in preoperative chemoradiotherapy and postoperative chemotherapy showed differing disease-free survival results, leaving its role in early-stage rectal cancer unclear. Image: ball-and-stick model of the drug.[4,5]

A study featured in a Poster Highlights Session (abstract 1514) found that consuming two or more servings of fish per week and 60 minutes of weekly exercise were each independently associated with a reduced risk of colon cancer recurrence. Photo by Â© ASCO/Todd Buchanan 2014.[6]